Infection of human alveolar macrophages by human coronavirus strain 229E

C. Joel Funk,1 Jieru Wang,1 Yoko Ito,1 Emily A. Travanty,1 Dennis R. Voelker,1 Kathryn V. Holmes2 and Robert J. Mason1

1National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
2Department of Microbiology, University of Colorado Denver, Aurora, CO 80045, USA

Correspondence
Robert J. Mason
masonb@njhealth.org

Received 4 October 2011
Accepted 14 November 2011

Human coronavirus strain 229E (HCoV-229E) commonly causes upper respiratory tract infections. However, lower respiratory tract infections can occur in some individuals, indicating that cells in the distal lung are susceptible to HCoV-229E. This study determined the virus susceptibility of primary cultures of human alveolar epithelial cells and alveolar macrophages (AMs). Fluorescent antibody staining indicated that HCoV-229E could readily infect AMs, but no evidence was found for infection in differentiated alveolar epithelial type II cells and only a very low level of infection in type II cells transitioning to the type I-like cell phenotype. However, a human bronchial epithelial cell line (16HBE) was readily infected. The innate immune response of AMs to HCoV-229E infection was evaluated for cytokine production and interferon (IFN) gene expression. AMs secreted significant amounts of tumour necrosis factor alpha (TNF-α), regulated on activation normal T-cell expressed and secreted (RANTES/CCL5) and macrophage inflammatory protein 1β (MIP-1/β/CCL4) in response to HCoV-229E infection, but these cells exhibited no detectable increase in IFN-β or interleukin-29 in mRNA levels. AMs from smokers had reduced secretion of TNF-α compared with non-smokers in response to HCoV-229E infection. Surfactant protein A (SP-A) and SP-D are part of the innate immune system in the distal lung. Both surfactant proteins bound to HCoV-229E, and pre-treatment of HCoV-229E with SP-A or SP-D inhibited infection of 16HBE cells. In contrast, there was a modest reduction in infection in AMs by SP-A, but not by SP-D. In summary, AMs are an important target for HCoV-229E, and they can mount a pro-inflammatory innate immune response to infection.

INTRODUCTION

Coronaviruses (CoVs) are large, enveloped, positive-sense RNA viruses that infect a broad range of vertebrates and cause disease of medical and veterinary significance. Infections are generally localized to the respiratory, enteric or nervous systems, but systemic disease can also be caused by some coronaviruses (Perlman, 1998). Currently five human CoVs (HCoVs) are recognized. Two HCoVs, strains 229E (HCoV-229E) and OC43, generally cause winter outbreaks of mild, self-limited upper respiratory tract infections. Identification of a novel CoV as the aetiological agent of the severe acute respiratory syndrome (SARS) epidemic of 2002–2003 led to an extensive survey to determine the role of CoVs in human respiratory diseases. The result was the discovery of two additional respiratory HCoVs, strains NL63 and HKU1 (Fouchier et al., 2004; van der Hoek et al., 2004; Woo et al., 2005). These newly discovered HCoVs mostly cause upper respiratory tract infections (Pyrc et al., 2007). However, all four of the non-SARS HCoVs can occasionally cause pneumonia and lower respiratory tract infections (Dominguez et al., 2009).

HCoV-229E is a common non-SARS HCoV, with about 90% of adults having detectable antibodies (Severance et al., 2008). As stated above, most infections produce symptoms of nasal discharge, cough and sore throat (Dijkman & van der Hoek, 2009). However, HCoV-229E infection has also occasionally been associated with lower respiratory tract infections in infants, the elderly or immunocompromised individuals (Dijkman & van der Hoek, 2009; El-Sahly et al., 2000; Graat et al., 2003; McIntosh et al., 1974; Pene et al., 2003). There is also continued interest in the role of CoV infections in causing exacerbations of patients with pre-existing lung disease, especially chronic obstructive pulmonary disease (COPD) (Beckham et al., 2005).

This study was undertaken to determine whether cell types found in the lower respiratory tract, namely, alveolar epithelial type II cells, type I-like cells and alveolar macrophages (AMs), were susceptible to HCoV-229E.
infection. Previously, HCoV-229E was shown to infect bronchial epithelial cells and blood monocyte-derived macrophages (Cheung et al., 2005; Desforges et al., 2007; Wang et al., 2000), but the responses of human alveolar epithelial cells and AMs have not been defined. We also determined whether the respiratory collectins surfactant protein A (SP-A) and SP-D could inhibit HCoV-229E infection.

RESULTS

Infection of primary cultures of differentiated human lung cells

Primary cultures of alveolar type II cells, alveolar type I-like cells and AMs were evaluated. These cells are located in the gas-exchange units of the lower respiratory tract. Differentiated type II cells were cultured as reported elsewhere (Wang et al., 2011). Type I-like cells are type II cells that spread out in culture and develop into a phenotype similar to type I cells in that they cease to express the surfactant proteins and express markers of type I cells (Wang et al., 2007). In the adult lung, type I cells are derived from type II cells (Fehrenbach, 2001), but isolation and culture of human type I cells have not been reported. Type II cells were refractory to HCoV-229E infection in all experiments, whereas a few type I-like cells were infected, but the overall level of infection in these cultures was very low, estimated to be <1%. Nevertheless, some of the infected type I-like cells formed syncytia that stained for viral antigens, which are indicative of CoV infection, but no other cytopathic effects were observed (Fig. 1a). The few fibroblasts that appeared in the epithelial cultures were readily infected (data not shown). In contrast, >50% of the human AMs were susceptible to HCoV-229E (Fig. 1a).

We also evaluated the susceptibility of several human respiratory epithelial cell lines, including the lung cancer cell line A549, the bronchial epithelial cell line 16HBE14o− (16HBE), and Calu-3, H292 and H441 cells, but only 16HBE cells (Fig. 1b) and A549 cells (data not shown) were susceptible to infection. We used plaque assays to measure the kinetics of release of infectious virus particles from AMs and 16HBE cells. Both AMs and 16HBE cells were productively infected by HCoV-229E, with a 15-fold increase in virus titre by 24 h post-inoculation. Samples taken at 48 h showed a drop in virus titre in AM cultures, but a further increase in 16HBE cultures (Fig. 2). Infection of A549 cells was not studied in further detail.

The susceptibility of the primary alveolar epithelial cells and macrophages could be related to the level of expression of the HCoV-229E receptor, aminopeptidase N (CD13/APN) (Yeager et al., 1992). The cellular expression level of CD13/APN was assessed by flow cytometry (Fig. 3). AMs, 16HBE cells, A549 cells and the fetal lung fibroblast line MRC-5 all expressed significant levels of CD13/APN. The MRC-5 cell line used to propagate HCoV-229E is known to express CD13/APN and served as a positive control in Fig. 3. Alveolar type I-like cells and Calu-3 cells expressed a low but detectable level of CD13/APN, whereas the level of CD13/APN was below the level of detection for alveolar type II cells and H292 and H441 cells. Hence, the expression of CD13 was related directly to their susceptibility to infection by HCoV-229E.

Fig. 1. Detection of cells infected with HCoV-229E. AMs, alveolar type I-like cells and 16HBE cells were cultured as described in Methods and infected with HCoV-229E. (a) Top row: alveolar epithelial type I-like cells were inoculated with HCoV-229E at an m.o.i. of 1, fixed at 24 h post-inoculation and immunostained for the epithelial cell marker cytokeratin (clone MNF116; red) and HCoV-229E proteins (green), and with DAPI to stain the nuclei (blue). Bottom row: AMs were inoculated with HCoV-229E at an m.o.i. of 1, fixed at 24 h post-inoculation and immunostained for CD68 (red) and HCoV-229E (green), and with DAPI (blue). (b) 16HBE cells were inoculated with HCoV-229E at an m.o.i. of 0.1 or control medium, fixed at 24 h post-inoculation and immunostained for CD68 (red) and HCoV-229E proteins (green) or with DAPI for the nuclei (blue).
Cytokine and interferon (IFN) response by AMs following HCoV-229E infection

As AMs were much more susceptible to HCoV-229E infection than alveolar epithelial cells, AMs were evaluated for their production of cytokines in response to HCoV-229E infection. To define the broad innate immune response to HCoV-229E infection, we initially used a multiplex assay. AMs from three different non-smoking donors were cultured and inoculated with HCoV-229E. The supernatant was collected at 24 h post-inoculation and the samples were analysed for 25 cytokines using an antibody bead-based Luminex assay. There was considerable variation in the levels of cytokines secreted by AMs from the three donors, but 11 of the 25 cytokines were detectable by this assay and increased in all three of the infected samples compared with the controls (Table 1). Of the cytokines tested, tumour necrosis factor alpha (TNF-α) showed the greatest increase following infection, but substantial increases in IFN-induced protein 10 (IP-10/CXCL10), macrophage inflammatory protein 1α (MIP-1α/CCL3), MIP-1β (CCL4), interleukin-7 (IL-7) and regulated on activation normal T-cell expressed and secreted (RANTES/CCL5) were also observed. In order to confirm the cytokine response in the multiplex study, we measured these proteins in culture supernatants in three additional experiments by ELISA. HCoV-229E infection of AMs increased the secretion of RANTES (CCL5), TNF-α and MIP-1β (CCL4) (Fig. 4a–c).

Because of the interest in CoV infections in smokers and in patients with COPD, we compared the secretion of cytokines in response to HCoV-229E infection in AMs isolated from smokers, ex-smokers and non-smokers (Beckham et al., 2005; El-Sahly et al., 2000). Unfortunately, the magnitude of the increase of TNF-α secretion after HCoV-229E infection was quite variable and there was not a consistent difference between macrophages from smokers, non-smokers or ex-smokers. However, there was an increase in TNF-α secretion following HCoV-229E infection in all groups except the ex-smokers, where the number of subjects was only four (see Supplementary Fig. S1, available in JGV Online). There was also no increase in TNF-α secretion when AMs were inoculated with UV-inactivated HCoV-229E (data not shown).

One of the most important responses of many cell types to virus infection is secretion of type I IFNs, which induce an antiviral state in surrounding cells. A Luminex assay detected a small increase in IFN-α from infected AMs (Table 1), but this assay did not measure the levels of other type I or type III IFNs. Therefore, we used quantitative PCR (qPCR) assays to measure mRNA levels of IFN-β (type I IFN) and IL-29/IFN-λ1 (type III IFN) and found no significant increase in either IFN after HCoV-229E infection (Fig. 4d). There was also no increase in IL-29 protein secretion during infection (data not shown).
Influenza infection markedly increases the mRNA levels of IFN-β and IL-29 in human AMs (Wang et al., 2009), so these cells are able to produce a type I and type III IFN response.

**Effects of SP-A and SP-D on HCoV-229E infection**

Surfactant proteins play a critical role in protecting the alveolus from inhaled pathogens (Haagsman et al., 2008; Hartshorn, 2010). We determined the binding of SP-A and SP-D to HCoV-229E virions using a solid-phase assay (Fig. 5a, b). Both surfactant proteins bound similarly to HCoV-229E virions in a dose-dependent manner. Virus binding was nearly saturated at 10 μg, indicating that 1 μg surfactant protein can bind about 10 μg virus. These results demonstrated that SP-A and SP-D have the capacity to bind HCoV-229E and suggested that surfactant proteins might modulate infection within the lower respiratory tract.

To assess the ability of SP-A and SP-D to block infection, we chose the cell line 16HBE, which does not contain endogenous SP-A or SP-D and is readily infected by HCoV-229E. Both SP-A and SP-D inhibited virus infection in a concentration-dependent manner (Fig. 5c). However, SP-D caused a greater reduction in HCoV-229E infection at both 3 and 10 μg ml⁻¹ than the same concentrations of SP-A. Treatment of the virus inoculum with 10 μg SP-D ml⁻¹ resulted in a >60% drop in the number of infected cells compared with wells without SP-D. However, the level of inhibition of virus infection was modest compared with the inhibition of influenza infection (H3N2) in Madin–Derby canine kidney (MDCK) cells assayed under the same conditions.

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Control (pg ml⁻¹)</th>
<th>HCoV-229E-inoculated (pg ml⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1Ra</td>
<td>323 ± 119</td>
<td>555 ± 183</td>
</tr>
<tr>
<td>IL-2R</td>
<td>1530 ± 640</td>
<td>2650 ± 690</td>
</tr>
<tr>
<td>IL-6</td>
<td>289 ± 214</td>
<td>511 ± 307</td>
</tr>
<tr>
<td>IL-7</td>
<td>72 ± 51</td>
<td>168 ± 58</td>
</tr>
<tr>
<td>IL-12p40/p70</td>
<td>95 ± 41</td>
<td>150 ± 43</td>
</tr>
<tr>
<td>TNF-α</td>
<td>155 ± 71</td>
<td>3190 ± 1410</td>
</tr>
<tr>
<td>IFN-α</td>
<td>33 ± 12</td>
<td>49 ± 6</td>
</tr>
<tr>
<td>MIP-1α/CCL3</td>
<td>6290 ± 2830</td>
<td>22000 ± 10400</td>
</tr>
<tr>
<td>MIP-1β/CCL4</td>
<td>3950 ± 1580</td>
<td>6930 ± 2750</td>
</tr>
<tr>
<td>IP-10/CXCL10</td>
<td>162 ± 143</td>
<td>874 ± 455</td>
</tr>
<tr>
<td>RANTES/CCL5</td>
<td>269 ± 203</td>
<td>544 ± 195</td>
</tr>
</tbody>
</table>

**Table 1. HCoV-229E infection increases secretion of cytokines by AMs.**

Culture supernatants from HCoV-229E-infected human AMs collected at 24 h post-inoculation were assayed by Luminex multiplex technology. The data represent means ± SEM of three independent donors.

**Fig. 4.** Cytokine secretion and IFN response by AMs in response to HCoV-229E infection. AMs were cultured and infected with HCoV-229E at an m.o.i. of 1 and the culture supernatants were collected 24 h later. (a–c) Levels of the cytokines TNF-α (a), RANTES (CCL5) (b) and MIP-1β (CCL4) (c) were measured by ELISA and compared with levels in the control medium (Ctrl). (d) mRNA levels of IFN-β and IL-29 in AMs from eight donors 24 h after inoculation with HCoV-229E or control medium.
DISCUSSION

Of the three human lung cell types that were evaluated, AMs were the most readily infected by HCoV-229E. AMs were not only susceptible to infection, but also released a significant amount of infectious virus. AMs have a critical role in preventing dust, toxins and pathogens from damaging the lung surface. The response of AMs to virus infection includes a central role in initiating the innate immune response, including secretion of cytokines. AMs produced a variety of cytokines in response to HCoV-229E infection, and these cytokines are known to activate or be chemotactic for monocytes, neutrophils and lymphocytes. The cytokines produced by AMs in our study were similar to the cytokines detected following HCoV-229E infection of human monocytes and the monocytic cell line THP-1 (Desforges et al., 2007).

Although HCoV-229E produced a cytokine response in AMs, it did not result in a significant increase in IFN expression. As AMs are considered to be an important source of type I IFNs following infection by RNA viruses (Kumagai et al., 2007), our results suggest that HCoV-229E may have a mechanism to block the IFN pathway in AMs. Several SARS-CoV gene products may downregulate or inhibit the IFN-signalling pathway during SARS-CoV infection (de Lang et al., 2009; Kopecky-Bromberg et al., 2006, 2007; Minakshi et al., 2009; Narayanan et al., 2008). Similar gene products of HCoV-229E may be able to inhibit IFN during infection of AMs and should be the subject of additional studies. However, it should be noted

Fig. 5. Binding and inhibition of infection of HCoV-229E by surfactant proteins SP-A and SP-D. The surfactant proteins were bound to an ELISA plate, followed sequentially by binding of the HCoV-229E virus, goat anti-HCoV-229E antibody and an HRP-conjugated anti-goat IgG antibody. (a, b) Binding curves for HCoV-229E bound to 1 µg SP-A (a) or SP-D (b) per well. (c) Inhibition of HCoV-229E infection of 16HBE cells after pre-incubation of the virus with SP-A or SP-D. The number of cells infected with virus alone was set at 100%, and this control was compared with cells that were infected with virus plus increasing concentrations of surfactant proteins. The results are shown as means ± SEM for three independent experiments. Open bars, SP-A; filled bars, SP-D. *P<0.05; **P<0.01. (d) Effect of SP-A and SP-D on HCoV-229E infectivity in human AMs. The number of cells infected with virus alone was set at 100%, and the effect of 10 µg SP-A ml⁻¹ (open bar) or 10 µg SP-D ml⁻¹ (filled bar) on HCoV-229E infection of human AMs (m.o.i. of 1) at 7 h post-inoculation is shown (n=3). *P<0.05.
that blood monocyte-derived macrophages were found to develop a type I and type III mRNA IFN response to HCoV-229E (Cheung et al., 2005). Hence, the differences in response might be due to functional differences between AMs and blood monocyte-derived macrophages. Additional studies are indicated to define further the IFN response to HCoV-229E.

The cellular tropism for AMs that we observed for HCoV-229E differed from the cellular tropism that we found for sialodacryoadenitis virus (SDAV), a rat CoV. SDAV readily infected bronchial and alveolar epithelial cells, especially type I cells, but not AMs (Funk et al., 2009). For SARS-CoV, we also found infection of alveolar type II cells, but not AMs (Mossel et al., 2008). The cellular tropism of HCoV-NL-63 and HCoV-HKU-1 needs to be defined more precisely, but both are reported to infect bronchial epithelial cells (Banach et al., 2009; Pyrc et al., 2010). Hence, some respiratory CoVs infect epithelial cells, whereas others infect AMs.

The ability of AMs to respond to virus infection is probably mediated in part by prior exposure to toxins and microorganisms that are present in air inhaled into the lung. One of the most common environmental exposures of human lungs is cigarette smoke. However, because of variability in the TNF-α response among donors, we were not able to demonstrate a difference in the TNF-α response to HCoV-229E based on smoking history. In a recent study on the cytokine response of monocyte-derived macrophages to influenza, there was also a significant variation in the cytokine response among individual donors (Sakabe et al., 2011). There is a well-known large variation in the response of human neutrophils to lipopolysaccharide (Wurfel et al., 2005). This individual variability poses a problem for experimental design, but highlights the potential importance of studying primary human cells. The biological basis for this variability is probably of clinical significance. In some other models of innate immunity, the levels of cytokine expression by AMs isolated from smokers are reduced compared with those from non-smokers (Chen et al., 2007). In a mouse-model system, when AMs from mice of a single genetic background were exposed to cigarette smoke and to poly(I:C), a mimic of viral dsRNA, there was a significant reduction in the levels of TNF-α, IL-6 and RANTES compared with AMs from control animals (Gaschler et al., 2008). Cigarette-smoke exposure probably also has additional effects beyond cytokine expression and alters the host response in other ways that were not the subject of our investigation.

Alveolar type II primary epithelial cells that were cultured in a system highly permissive for influenza infection were found to be refractory to infection with HCoV-229E (Wang et al., 2009, 2011). However, a few type I-like cells could be infected. Because of the very low level of infection of type I-like cells, we did not evaluate their cytokine or IFN response. The very low level of infection of type I-like cells and the absence of infection in type II cells was probably due to the very low level of expression of the receptor CD13/APN (Fig. 3). It was interesting to note the large variation in expression of CD13/APN in different epithelial lung cell lines. This indicates the importance of verifying the results in cell lines with primary cultures. 16HBE, H292 and Calu-3 cells are all used as models of bronchial epithelial cells, but have marked differences in expression of CD13/APN. Although A549 cells do not express surfactant proteins, they are sometimes used as a model of alveolar type II cells. In this study, we found another difference: A549 cells expressed CD13 and were susceptible to HCoV-229E, whereas human type II cells did not express CD13 and did not support HCoV-229E infection.

SP-A and SP-D have been shown to be important components of innate immunity in the lung and are potentially very important for influenza infections, including the 2009 pandemic H1N1 infections (Hartshorn et al., 2000; Job et al., 2010). SP-D binds to carbohydrates on the influenza haemagglutinin and neuraminidase by its carbohydrate-recognition domain (Job et al., 2010; Reading et al., 1997). SP-D binding to haemagglutinin inhibits both virus infection and haemagglutination activity. SP-A interacts with influenza primarily through sialic acid residues on N-linked carbohydrates of SP-A and not through its carbohydrate-recognition domain, but it can also inhibit infection. SP-D binds the SARS-CoV surface spike protein, although the effects of SP-D in SARS infection have not been determined (Leth-Larsen et al., 2007). Our study indicated that both SP-A and SP-D bound HCoV-229E. SP-D was more effective at inhibiting infection of 16HBE cells and SP-A was more effective at inhibiting infection of AMs. As we tested both the SP-A and SP-D preparations for inhibition of infection of MDCK cells by influenza virus (Supplementary Fig. S2), we knew that the proteins were biologically active. In addition, the level of the surfactant proteins in alveolar lavage fluid may increase during the course of infection and impede propagation of infection into the distal lung. For example, in SDAV infection of rats, SP-D but not SP-A levels increase in lavage fluid during the course of the infection as it resolves (Funk et al., 2009).

In conclusion, the cellular environment of the alveolus is not very conducive to HCoV-229E production. Neither differentiated alveolar type II nor type I-like epithelial cells were infected easily in vitro, and SP-A and SP-D might provide some level of protection. Although AMs could be infected, they did not appear to produce large amounts of virus. When AMs became infected, they secreted cytokines and chemokines that can attract other immune cells capable of aiding in the destruction of infected cells. Although no single factor was identified, lower respiratory tract infections of HCoV-229E probably require some compromise of the normal innate immune system. For example, many cases of lower respiratory tract infections involve patients that are diagnosed as immunocompromised or have been co-infected with another respiratory
et al. AMs were plated at a density of $2 \times 10^6$ or $5 \times 10^5$ cm$^{-2}$ in DMEM with 10 % FBS and antibiotics (Wang et al., 2007). The red blood cells were lysed with Pharm Lyse (BD Biosciences) and macrophages were either plated immediately or resuspended in freezing medium (10 % DMSO and 90 % FBS) and stored in aliquots in liquid nitrogen for use at a later time. Further treatment of the lung for isolation of type II epithelial cells involved digestion with elastase and isolation of the cells by differential centrifugation and gradient purification (Wang et al., 2011). Macrophages were removed from the cell suspension using negative selection with CD14-coated Dynal magnetic beads (Invitrogen) and IgG-coated Petri dishes. Assessment of cell purity was made by staining for cytokeratin (mAb clone CAM 5.2; DakoCytomation). Epithelial cells were either plated immediately or resuspended in freezing medium and stored in aliquots in liquid nitrogen.

**Cell culture.** AMs were resuspended in DMEM supplemented with 10 % FBS, 2 mM glutamine and antibiotics (2.5 g amphotericin B ml$^{-1}$, 100 g streptomycin ml$^{-1}$, 100 U penicillin G ml$^{-1}$ and 10 g gentamicin ml$^{-1}$) and plated on tissue-culture plates or glass coverslips. After a 2 h or overnight incubation to allow adherence, the cells were washed with DMEM to remove the non-adherent cells. The purity of isolated AMs was typically 90 % before plating and close to 100 % after adherence in culture, as measured by CD68 staining. AMs were plated at a density of $2 \times 10^5$ or $5 \times 10^4$ cm$^{-2}$ depending on the experiment. AMs were cultured for at least 2 days before infection. Most infections were carried out on AMs cultured for 2 days.

Alveolar epithelial type II cells were cultured in DMEM supplemented with 10 % FBS, 2 mM glutamine and antibiotics as above. Cells were plated on Millicell inserts (Millipore) that had previously been coated with a mixture of rat-tail collagen and Matrigel (BD Biosciences) in 10 % FBS. The cells were cultured in DMEM with 1 % charcoal-stripped FBS along with keratinocyte growth factor, isobutylmethylxanthine, 8-bromo-cAMP, dexamethasone and antibiotics to achieve their differentiated phenotype, as described previously (Wang et al., 2007, 2011).

Transdifferentiation of type II cells into type 1-like cells was accomplished by plating cells on rat-tail collagen-coated dishes or glass coverslips at a density of $0.5 \times 10^5$ or $1 \times 10^5$ cm$^{-2}$ in DMEM with 10 % FBS and antibiotics (Wang et al., 2007). After 24–48 h for adherence, the medium was changed to DMEM with 5 % FBS and cultured for an additional 6 days. These cells differentiate towards the type I cell phenotype but retain some type II cell features, such as remnant lamellar bodies. 16HBE cells were originally isolated from human bronchial epithelial cells and transformed with the origin-defective simian virus 40 genome (Cozens et al., 1994). The 16HBE cells used in this study grow readily in monolayers and were obtained from Marc Hershenson (University of Michigan, MI, USA; Page et al., 2003). This cell line was grown on tissue-culture plates or glass coverslips using DMEM with 10 % FBS and antibiotics.
5 mM CaCl2 incubation with buffer A. The binding of HCoV-229E to surfactant protein was determined secondary antibodies were each incubated at 37°C for 1 h. After incubation, the wells were washed three times with washing buffer using a vacuum manifold. A secondary PE-conjugated antibody was added for 45 min, the wells were washed twice and the samples were analysed using a Bio-Plex fluorescent reader (Bio-Rad). One hundred beads were counted for each analyte per well and values (pg ml⁻¹) were calculated using the Bio-Plex Manager software (Bio-Rad).

Cytokine ELISAs. Medium from virus-inoculated or control cells was harvested at 24 h after inoculation for the measurement of TNF-α, RANTES (CCL5) and MIP-1β (CCL4). ELISAs were purchased from ElisaTech and developed according to the kit instructions. Measurements were made from at least three independent human donor samples with reported values shown as means ± SEM of at least two replicate wells.

Flow cytometry. AMs, type-I like alveolar epithelial cells, type II cells and cell lines (16HBE, A549, H292, H441, Calu-3 and MRC-5) were cultured as for infection. Cells were removed from the culture surface with trypsin. After blocking with human Fc receptor blocking reagent (Miltenyi Biotec), the cells were stained with anti-human CD13/BDAP antibody (BD Biosciences) or isotype control (BD Pharmingen), followed by secondary PE-conjugated anti-mouse IgG antibody (Jackson ImmunoResearch). Samples were analysed on a BD LSRII flow cytometer (National Jewish Health Flow Core). We did not systematically evaluate the effect of trypsin on CD13 expression in these studies, and the values indicate relative expression and not the precise level of expression.

Surfactant protein solid-phase assay. Purified surfactant proteins (SP-A or SP-D) were coated onto microtiter wells (1 μg per well in 0.1 M NaHCO₃, pH 9.6) and incubated at 4°C overnight. SP-A was isolated from alveolar proteinosis lavage fluid and SP-D was a human recombinant protein. Non-specific binding was prevented by incubation with buffer A [20 mM Tris/HC1 (pH 7.4), 150 NaCl, 5 mM CaCl₂] in 3% powdered milk. Virus protein, in the amount indicated in the text, was incubated at 37°C for 1 h in buffer A. Following the incubation period, the wells were washed with buffer A and 3% skimmed milk. A goat anti-HCoV-229E antibody was used for detection of the virus, followed by incubation with a secondary HRP-conjugated rabbit anti-goat antibody. The primary and secondary antibodies were each incubated at 37°C for 1 h in buffer A. The binding of HCoV-229E to surfactant protein was determined using o-phenylenediamine as a substrate for the peroxidase reaction and measured by absorbance at 492 nm (A₄₉₂). Control conditions included wells without added viral protein.

Real-time qPCR. Measurement of IFN mRNA levels was performed with qPCR. The primers and probes for IFN-β and IL-29 TaqMan assays (Applied Biosystems) have been described previously (Wang et al., 2009). Expression of 36B4 (the acidic ribosomal phosphoprotein P0) was used to normalize the amount of mRNA for each sample (Wang et al., 2007).

Statistical analysis. Statistical analyses were performed using GraphPad Prism 4. A paired t-test was used to compare the difference between two groups. One-way analysis of variance was used to compare the difference among two or more groups. Appropriate post-hoc tests were selected for multiple comparisons. A value of P<0.05 was considered significant for all methods. The effect of HCoV-229E on TNF-α secretion (legend to Supplementary Fig. S1) was carried out by a Wilcoxon non-parametric t-test.

ACKNOWLEDGEMENTS

The 16HBE cells were a kind gift from Marc Hershenson (University of Michigan, MI, USA). We thank Dr Hong Wei Chu and his laboratory for support with the project. We also thank Rizwan Manzer, Karen Edeen and Beata Kosmidier for assistance with human type II cell and AM isolations. We thank Mandy Evans for performing some of the SP-A and SP-D binding studies. Finally, we thank Lydia Orth and Teneke M. Warren for assistance with manuscript preparation. This work was supported by grants from the National Institutes of Health (AI059576 and AI082982) and a grant from the ExxonMobil Foundation.

REFERENCES


